

BIOGRAPHICAL SKETCH

NAME: George A. Cioffi, MD

POSITION TITLE: Chairman, Department of Ophthalmology; Senior Vice President/Chief Medical Officer

INSTITUTION AND LOCATION: Legacy Health System, Portland, Oregon

	DEGREE	YEAR(s)	FIELD OF STUDY
University of Vermont, Burlington, Vt.	B.S.	1983	Zoology
University of South Carolina, Columbia, S.C.	M.D.	1987	Medicine

A. Positions and Honors

Positions and Employment

Surgical Intern, University of Hawaii	1987-1988
Ophthalmology Resident, University of Maryland	1988-1991
Research & Clinical Glaucoma Fellowship, Devers Eye Institute, Portland, OR	1991-1992
Staff Ophthalmologist, Clinician/Researcher, Devers Eye Institute, Portland, OR	1992-1997
Associate Scientist, Dow Neurological Institute, Portland, OR	1993-1997
Senior Scientist, Legacy Health System, Portland, OR	1997-Present
Director, Discoveries in Sight, Legacy Health System, Portland, OR	1997-2005
Director, Glaucoma Service, Devers Eye Institute, Portland, OR	1998-Present
Associate Clinical Professor, OR Health Sciences University, Portland, OR	1999-2004
Professor of Ophthalmology, Oregon Health Sciences University, Portland, OR	2005-Present
Section Head, Ophthalmology Section, Legacy Health System, Portland, OR	2002-2007
Endowed Chair, E. Michael Van Buskirk Chair of Ophthalmic Research, Devers Eye Institute, Portland, OR	2002-2005
RG Chenoweth Endowed Chair of Ophthalmology, Devers Eye Institute	2005-Present
Senior Vice President/Chief Medical Officer, Legacy Health System, Portland, OR	2007-Present

Honors

Phi Beta Kappa, University of Vermont	1982
Magna Cum Laude, University of Vermont	1983
Moody Award for Biologic Research, University of Vermont	1983
Cum Laude, University of S. Carolina	1987
Chief Resident, University of Maryland	1990-1991
ARVO Travel Fellowship Grant	1991
Honor Award, American Academy of Ophthalmology	1998
Best Doctors in America	2002-Present
Van Buskirk Chair of Ophthalmology Research	2002
R.G. Chenoweth Endowed Chair of Ophthalmology	2004
Senior Achievement Award, American Acad of Ophthalmology	2005
Sivalingam Lecture, Glaucoma, Wills Eye Hospital, Philadelphia	2005
Sanchez Salorio Lecture, Segovia, Spain	2005
American Glaucoma Society Clinician-Scientist Lectureship	2006
Schoenberg Lecture, University of Illinois, Chicago	2008

Editorial Boards

Journal of Glaucoma, Editor in Chief	2006-Present
Graefe's Archives of Ophthalmology	2000-Present

Advisory Boards

Food & Drug Administration	1998-2006
Prevent Blindness America, Glaucoma Advisory Committee	1999-Present
The Association for Research in Vision and Ophthalmology, Program Committee	1998-2000
Glaucoma Research Foundation, Scientific Advisory Board	2000-2001
Chairman	2002-Present
American Glaucoma Society, Chairman, Communication/Education	2001-2006

B. Selected peer-reviewed publications from over 140 publications (in chronological order).

1. **Cioffi GA**, Mansberger S, Spry P, Johnson C and Van Buskirk E M, Frequency doubling perimetry and the detection of eye disease in the community. *Trans Am Ophthalmol Soc* 2000 98: 195-199.
2. Mansberger S L, and **Cioffi GA**, Eyelash formation secondary to latanoprost treatment in a patient with alopecia. *Arch Ophthalmol* 2000 118: 718-719.
3. Zhao D Y, and **Cioffi GA**, Anterior optic nerve microvascular changes in human glaucomatous optic neuropathy. *Eye* 2000 14 (Pt 3B): 445-449.
4. **Cioffi GA**, Three common assumptions about ocular blood flow and glaucoma. *Surv Ophthalmol* 2001 45 Suppl 3: S325-331.
5. **Cioffi GA**, and Alm A, Measurement of ocular blood flow. *J Glaucoma* 2001 10: S62-64.
6. Fortune B, Johnson C A and **Cioffi GA**, The topographic relationship between multifocal electroretinographic and behavioral perimetric measures of function in glaucoma. *Optom Vis Sci* 2001 78: 206-214.
7. Mansberger S L, Passo M S, Schallock P I and **Cioffi GA**, Predictive value of a 1-day, 1-eye trial on the 1-month ocular hypotensive response of latanoprost 0.005%. *Am J Ophthalmol* 2001 132: 869-871.
8. Wang L, Cull G and **Cioffi GA**, Depth of penetration of scanning laser Doppler flowmetry in the primate optic nerve. *Arch Ophthalmol* 2001 119: 1810-1814.
9. Fortune B, Bearnse M a, Jr., **Cioffi GA** and Johnson C A, Selective loss of an oscillatory component from temporal retinal multifocal ERG responses in glaucoma. *Invest Ophthalmol Vis Sci* 2002a 43: 2638-2647.
10. Fortune B, Cull G, Wang L, Van Buskirk E M and **Cioffi GA**, Factors affecting the use of multifocal electroretinography to monitor function in a primate model of glaucoma. *Doc Ophthalmol* 2002b 105: 151-178.
11. Johnson C A, Sample P A, Cioffi GA, Liebmann J R and Weinreb R N, Structure and function evaluation (SAFE): I. criteria for glaucomatous visual field loss using standard automated perimetry (SAP) and short wavelength automated perimetry (SWAP). *Am J Ophthalmol* 2002 134: 177-185.
12. Mckendrick a M, **Cioffi GA** and Johnson C A, Short-wavelength sensitivity deficits in patients with migraine. *Arch Ophthalmol* 2002 120: 154-161.
13. Wang L, **Cioffi GA**, Cull G, Dong J and Fortune B, Immunohistologic evidence for retinal glial cell changes in human glaucoma. *Invest Ophthalmol Vis Sci* 2002 43: 1088-1094.
14. Bui B V, Fortune B, Cull G, Wang L and **Cioffi GA**, Baseline characteristics of the transient pattern electroretinogram in non-human primates: inter-ocular and inter-session variability. *Exp Eye Res* 2003 77: 555-566.
15. Cull G, **Cioffi GA**, Dong J, Homer L and Wang L, Estimating normal optic nerve axon numbers in non-human primate eyes. *J Glaucoma* 2003 12: 301-306.
16. Fortune B, Wang L, Bui B V, Cull G, Dong J and **Cioffi GA**, Local ganglion cell contributions to the macaque electroretinogram revealed by experimental nerve fiber layer bundle defect. *Invest Ophthalmol Vis Sci* 2003 44: 4567-4579.
17. Johnson C A, Sample P A, Zangwill L M, Vasile C G, **Cioffi GA**, Liebmann J R and Weinreb R N, Structure and function evaluation (SAFE): II. Comparison of optic disk and visual field characteristics. *Am J Ophthalmol* 2003 135: 148-154.
18. Wang L, Dong J, Cull G, Fortune B and **Cioffi GA**, Varicosities of intraretinal ganglion cell axons in human and nonhuman primates. *Invest Ophthalmol Vis Sci* 2003 44: 2-9.
19. **Cioffi GA**, Latina M A and Schwartz G F, Argon versus selective laser trabeculoplasty. *J Glaucoma* 2004 13: 174-177.
20. Fortune B, Bui B V, Cull G, Wang L and **Cioffi GA**, Inter-ocular and inter-session reliability of the electroretinogram photopic negative response (PhNR) in non-human primates. *Exp Eye Res* 2004a 78: 83-93.
21. Fortune B, Bui B V, Morrison J C, Johnson E C, Dong J, Cepurna W O, Jia L, Barber S and **Cioffi GA**, Selective ganglion cell functional loss in rats with experimental glaucoma. *Invest Ophthalmol Vis Sci* 2004b 45: 1854-1862.
22. **Cioffi, GA**. "Ischemic Model of Optic Nerve Injury", American Ophth Soc Thesis, *Trans of the Am Ophth Society*, 2005 103:592-613
23. Fortune B, Wang L, Bui B V, Burgoyne C F and **Cioffi GA**, Idiopathic bilateral optic atrophy in rhesus macaque. *Invest Ophthalmol Vis Sci* 2006 46(11):3943-56
24. Wang L, Fortune B, Cull G, Dong J, **Cioffi GA**. "Endothelin B Receptor in Human Glaucoma and Experimentally Induced Optic Nerve Damage", *Archives Ophthalmol* 2006 124(5):717-24
25. Fortune B, Wang L, Bui BV, Burgoyne CF, **Cioffi GA**, "Idiopathic Bilateral Optic Atrophy in Rhesus Macaque", *Invest_Ophthalmol Vis Sci*. 2006 46(11):3943-56
26. Mansberger SL, **Cioffi GA**, "The Probability of Glaucoma From Ocular Hypertension Determined by Ophthalmologists in Comparison to a Risk Calculator", *J Glaucoma* 2006 15(5):426-31
27. Fortune B., Demirel S, Zhang X, Hood DC, Patterson E., Jamil A, Mansberger SL, **Cioffi GA**, Johnson CA, "Comparing Multifocal VEP and Standard Automated Perimetry in High-Risk Ocular Hypertension and Early Glaucoma", *Invest Ophthalmol Vis Sci*, 2007 48(3):1173-80
28. Wang L, Fortune B, Cull G, McElwain KM, **Cioffi GA**, "Microspheres Method for Ocular Blood Flow Measurement in Rats: Size and Dose Optimization", *Exp Eye Res*, 2007 84(1):108-17
29. Mansberger SL, Johnson CA, **Cioffi GA**, "The Results of Screening Frequency Doubling Technology Perimetry in Different Locations of the Community", *J Glaucoma*, 2007 16(1):73-80

30. Mansberger SL, Huges BA, Gordon MO, Spaner SD, Baiser JA, **Cioffi GA**, and the OHTS Group, "Comparison of IOP response to Topical Beta-Adrenergic Antagonists and Prostaglandin Analogues in African Americans and Whites: The Ocular Hypertension Treatment Study (OHTS)", Arch Ophthalmol 2007 125:454-499
31. Mansberger SL, Patterson E, Nguyen H, **Cioffi GA**, "Late Onset Proptosis with Baerveldt Glaucoma Implants", Letter to the Editor, BJO In Press, 2007

C. Research Support

Ongoing Research Support

5 R01 EY05231-17 Cioffi (PI) 4/01/90-6/30/05

NIH/NEI - "Uveal Vasculature: Optic Nerve Microcirculation"

The major goals of this project are to determine the basis of early glaucomatous damage and to define optimal methods of detecting early glaucomatous visual function loss. Role: Principal Investigator

EY-10362-11 Cioffi (PI) 01/01/94 to 12/31/2008

NIH/NEI - "Ocular Hypertension Treatment Study II" (OHTS II)

The major goals of this project are to determine whether reduction of intraocular hypertension with eye drop medicines prevents or delays the onset of glaucoma in individuals with increased eye pressure. The aim of the study's new phase, OHTS II, is to determine whether eye drops to lower pressure are as effective when started later compared to earlier treatment and to also determine how long it takes for the pressure lowering eye drops to have their full protective effect against the development of glaucoma. Role: Principal Investigator

5 R01 EY03424-25 Johnson (PI) 1/01/81-3/31/07

NIH/NEI - "Perimetry and Psychophysics in Glaucoma"

The major goal of this project is to investigate a new technique for monitoring retinal ganglion cell loss in glaucoma, the multifocal Visual Evoked Potential, and evaluate the ability of a functional (flicker adaptation abnormalities) and a structural (optic nerve head topography) indicator of early glaucomatous damage to predict the onset and location of future visual field loss. Role: Co-Investigator

EY-015267 Saugstad (PI) 12/01/03 to 11/30/06

NIH/NEI - "Role of Acid-Sensing Ion Channels in Glaucoma"

The major goals of this project are to ascertain the molecular mechanisms that contribute to retinal and optic nerve injury or death in glaucoma. Role: Co-Investigator

1 K23 EY015501-01 Mansberger (PI) 06/01/04 - 05/31/09

NIH/NEI - "The Northwest Tribal Vision Project"

The major goals of the project are to determine if non-MD, non-OD paraprofessionals (such as ophthalmic technicians) performing newer methods of testing have good diagnostic precision and feasibility in comparison to an expert examiner; to attain preliminary data regarding the age-specific prevalence of visual impairment, blindness, and ocular disease in a sample of Northwest American Indians and Alaskan Natives (AI/AN) aged 40 years and older. This project is under the direction of a mentorship committee. Role: Consultant, Mentor Committee

1 U48 DP00024-01 (Becker) 9/30/04 to 9/29/09

DHHS/CDC - "Center for Healthy Native Communities"

The major goals of this project are to address the health promotion and chronic disease prevention needs of regional tribal and other underserved communities through community-based participatory research, and through training, dissemination, and evaluation activities. The initial core projects are focused on disability prevention related to vision and hearing loss – new areas for community-based prevention research. Role: Co-Investigator